Image by freepikPurespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
Tag Archive for: Sofinnova Partners
SR-TigitItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia (MMA) to Phase I/II testing.